Skip to main content
A Singapore Government Agency Website

Temporary suspension of the sales of Esmya™ (ulipristal acetate) Tablet 5mg

A Dear Healthcare Professional Letter has been issued by Zuellig Pharma Pte Ltd to update healthcare professionals on the temporary suspension of the sales of Esmya (ulipristal acetate) Tablet 5mg. This is due to ongoing concerns of its association with liver injuries, the most recent of which involved an overseas report of serious liver injury resulting in liver transplantation that was surfaced by the European Medicines Agency (EMA). The temporary suspension is implemented as a precautionary measure while HSA reassesses the benefit-risk profile of Esmya. Please refer to the letter for HSA's advisory and further details on this issue.
Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

26 Mar 2020

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.